Published in Hepatology on March 20, 2015
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol (2015) 0.95
IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog (2016) 0.81
The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Surg Today (2017) 0.79
Interleukin-1 Family Cytokines in Liver Diseases. Mediators Inflamm (2015) 0.79
Emerging Molecular Therapeutic Targets for Cholangiocarcinoma. J Hepatol (2017) 0.78
Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol (2016) 0.78
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology (2016) 0.78
A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem (2016) 0.78
Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis. Gastroenterology (2016) 0.75
Current Strategies to Generate Mature Human induced Pluripotent Stem Cells Derived Cholangiocytes and Future Applications. Organogenesis (2017) 0.75
Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep (2016) 0.75
Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma. Mol Clin Oncol (2017) 0.75
The case for immune-based approaches in biliary tract carcinoma. Hepatology (2016) 0.75
The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Front Immunol (2017) 0.75
Gene expression patterns in CD4+ peripheral blood cells in healthy subjects and stage IV melanoma patients. Cancer Immunol Immunother (2015) 0.75
Biliary tract. A new mouse model that closely resembles human cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2015) 0.75
Platelet-Derived Growth Factor Regulates YAP Transcriptional Activity via Src Family Kinase Dependent Tyrosine Phosphorylation. J Cell Biochem (2017) 0.75
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression. J Hepatol (2017) 0.75
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol (2009) 235.12
TopHat: discovering splice junctions with RNA-Seq. Bioinformatics (2009) 81.13
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (2009) 67.17
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
RSeQC: quality control of RNA-seq experiments. Bioinformatics (2012) 4.31
Risk factors for cholangiocarcinoma. Hepatology (2011) 3.27
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology (2009) 3.03
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines. Am J Physiol (1994) 2.36
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology (2014) 1.84
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol (2014) 1.44
Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med (2009) 1.36
MAP-RSeq: Mayo Analysis Pipeline for RNA sequencing. BMC Bioinformatics (2014) 1.35
Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int (2011) 1.31
The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.26
Primary culture of cholangiocytes from normal mouse liver. In Vitro Cell Dev Biol Anim (1998) 1.12
Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation. J Biol Chem (2011) 1.07
BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther (2008) 1.07
Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol (2010) 1.01
HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol (2013) 0.97
Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol (2004) 0.93
Animal models of cholangiocarcinoma. Curr Opin Gastroenterol (2013) 0.88
Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. J Biol Chem (2014) 0.88
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34
BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat Biotechnol (2002) 6.20
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
dbCAN: a web resource for automated carbohydrate-active enzyme annotation. Nucleic Acids Res (2012) 4.91
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A (2003) 4.67
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol (2004) 3.84
The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab (2012) 3.81
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Directed neural differentiation of human embryonic stem cells via an obligated primitive anterior stage. Stem Cells (2007) 3.71
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Multigait soft robot. Proc Natl Acad Sci U S A (2011) 3.57
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci U S A (2007) 3.20
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature (2011) 3.19
Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol (2007) 3.17
Cholangiocarcinoma. Gastroenterology (2005) 3.15
[GSDS: a gene structure display server]. Yi Chuan (2007) 3.02
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Lysosomes in cell death. Oncogene (2004) 3.00
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Ultrafast dynamics of solute-solvent complexation observed at thermal equilibrium in real time. Science (2005) 2.88
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. Nature (2013) 2.52
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology (2010) 2.48
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
Obstruction of extrahepatic bile ducts by lymphocytes is regulated by IFN-gamma in experimental biliary atresia. J Clin Invest (2004) 2.40
Life and death by death receptors. FASEB J (2009) 2.39
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Testis-specific TAF homologs collaborate to control a tissue-specific transcription program. Development (2004) 2.35
Cholangiocarcinoma. Clin Liver Dis (2008) 2.33
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem (2010) 2.30
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia. Hepatology (2004) 2.28
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res (2003) 2.27
Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res (2002) 2.27
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res (2005) 2.23
Single ion-channel recordings using glass nanopore membranes. J Am Chem Soc (2007) 2.22
Gene expression signature for biliary atresia and a role for interleukin-8 in pathogenesis of experimental disease. Hepatology (2014) 2.20
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol (2011) 2.18
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
PlantTFDB: a comprehensive plant transcription factor database. Nucleic Acids Res (2007) 2.17
PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res (2008) 2.16
Soft robotics for chemists. Angew Chem Int Ed Engl (2011) 2.14
MSOAR: a high-throughput ortholog assignment system based on genome rearrangement. J Comput Biol (2007) 2.14
S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med (2010) 2.13
Neonatal NK cells target the mouse duct epithelium via Nkg2d and drive tissue-specific injury in experimental biliary atresia. J Clin Invest (2009) 2.08
Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol (2007) 2.08
Electrochemical sensing in paper-based microfluidic devices. Lab Chip (2009) 2.06
Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer (2005) 2.06
Phosphorylation of histone H4 Ser1 regulates sporulation in yeast and is conserved in fly and mouse spermatogenesis. Genes Dev (2006) 2.05
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Independent and overlapping transcriptional activation during liver development and regeneration in mice. Hepatology (2002) 2.02
Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
High incidence of epithelial cancers in mice deficient for DNA polymerase delta proofreading. Proc Natl Acad Sci U S A (2002) 1.95
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93